ASH: Hodgkin's Lymphoma Tx Shows Promise in Small Trial

This article originally appeared here.
Share this content:
ASH: Hodgkin's Lymphoma Tx Shows Promise in Small Trial
ASH: Hodgkin's Lymphoma Tx Shows Promise in Small Trial

MONDAY, Dec. 8, 2014 (HealthDay News) -- In a small new trial, a form of treatment based on the body's immune system appears to be helping patients with Hodgkin's lymphoma for whom other treatments have failed. The study was published online Dec. 6 in the New England Journal of Medicine to coincide with its expected presentation on Saturday at the annual meeting of the American Society of Hematology, held from Dec. 6 to 9 in San Francisco.

According to researchers at the Dana-Farber Cancer Institute in Boston, more than one-third of the 23 patients studied had tried -- and ultimately failed -- at least six lines of treatment. Four-fifths of the patients had also undergone stem cell transplant therapy in hopes of curing their disease, but that also failed. The new phase 1 trial involved nivolumab, a novel PD-1-blocking antibody, hypothesized to inhibit tumor immune evasion in patients with relapsed or refractory Hodgkin's lymphoma.

Following treatment, four of the patients had no detectable tumor left and the tumors in 16 other patients had shrunk to less than half of their original size, the researchers said. Six months after treatment, 86 percent of patients were alive and continued to show response to the therapy. One year after treatment, most of the patients continued to do well. About 20 percent of the patients had serious treatment-related side effects, but none of them were life threatening.

"What makes these results especially encouraging is that they were achieved in patients who had exhausted other treatment options," study co-senior author Margaret Shipp, M.D., chief of the division of hematologic neoplasia at the Dana-Farber Cancer Institute, said in an institute news release. "We're also excited by the duration of responses to the drug: The majority of patients who had a response are still doing well more than a year after their treatment."

The study received funding from Bristol-Myers Squibb, which markets nivolumab.

Abstract
Full Text
Editorial
More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »